What's Happening?
A recent Phase 3 study, published in the British Journal of Dermatology and reported by Dermatology Times, has shown promising results for Skyrizi (risankizumab) in treating moderate to severe plaque psoriasis in children and adolescents. The study included
137 patients aged 6 to 17. Among teens aged 12 to 17, 41% of those treated with Skyrizi achieved completely clear skin after 16 weeks, compared to 18% in the Stelara group. For younger children aged 6 to 11, 43% achieved completely clear skin by week 16, with 90% having clear or almost clear skin. Patients also reported reduced itching and less interference with daily life due to psoriasis, with these improvements sustained at the one-year mark. Skyrizi functions by blocking IL-23, an immune signal contributing to psoriasis inflammation. The FDA approved Skyrizi in June for children aged 6 and older who are candidates for systemic treatment or light therapy, including a smaller-dose syringe for children under approximately 88 pounds. After two initial doses four weeks apart, the medication is administered every 12 weeks.
Why It's Important?
This development is significant for the estimated one-third of individuals with psoriasis who experience its onset in childhood. The availability of an effective treatment like Skyrizi offers a new and impactful option for parents and pediatric dermatologists seeking to manage this chronic condition. Psoriasis can significantly affect a child's quality of life, impacting daily activities and causing discomfort. The study's findings, particularly the high percentage of patients achieving clear or almost clear skin and reporting reduced itching, suggest a substantial improvement in patient outcomes. The FDA approval provides a clear pathway for healthcare providers to prescribe Skyrizi, potentially leading to better long-term management of pediatric psoriasis and improved well-being for affected children and their families. The long-term monitoring of side effects, consistent with those observed in adults, remains a crucial aspect of its use.
What's Next?
Following the FDA approval, Skyrizi is now available as a treatment option for children aged 6 and older with moderate to severe plaque psoriasis. Parents of children with psoriasis that is not responding to topical treatments are encouraged to consult with a board-certified dermatologist to discuss whether a biologic like Skyrizi is appropriate. Continued monitoring of patients, particularly for long-term side effects, will be important. The study also highlighted that discontinuing the drug can lead to flares, but restarting treatment can restore improvement, indicating the chronic nature of psoriasis and the need for ongoing management. Further research may explore optimal treatment durations, combinations with other therapies, and the long-term impact on pediatric patients' overall health and development.
Beyond the Headlines
The introduction of Skyrizi for pediatric psoriasis underscores the ongoing advancements in targeted therapies for autoimmune diseases. This specific approval highlights a growing recognition of the unique needs of pediatric populations in clinical research and drug development. Beyond the immediate medical benefits, effective treatment of childhood psoriasis can have profound psychological and social impacts, reducing stigma, improving self-esteem, and enabling children to participate more fully in school and social activities. The success of biologics like Skyrizi also points to a future where treatments are increasingly tailored to specific immunological pathways, offering more precise and effective interventions for a range of inflammatory conditions. This also raises questions about access to such advanced treatments, given their cost, and the need for equitable healthcare solutions.













